Sentinel lymph node mapping for carcinoma of the colon: A pilot study

G. S. Waters, K. R. Geisinger, D. D. Garske, Brian W. Loggie, E. A. Levine, E. F. Foley, K. W. Sharp

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Sentinel lymph node (SLN) mapping has evolved into the standard of care for melanoma and may replace routine node dissection in the treatment of breast cancer. There are few data evaluating sentinel node mapping in patients with cancer of the colon. This trial represents our initial experience with SLN mapping for carcinoma of the colon. SLN mapping was performed in 22 patients most of whom had biopsy-proven adenocarcinoma of the colon. One milliliter of isosulfan blue was injected with a 25-gauge needle into the subserosa at four sites around the edge of the palpable tumor. The SLN was identified visually and excised. A standard lymphadenectomy was then performed. The SLN was analyzed with standard hematoxylin and eosin evaluation. Immunohistochemical techniques for carcinoembryonic antigen and cytokeratin (Imm) were performed if the H and E was negative. The mapping added approximately 5 minutes to the total operative time and no adverse reactions to the dye occurred. A SLN was identified in 20 of 22 cases. In cases with negative lymph nodes the SLN was predictive of all the regional nodes by both H and E and Imm (14 of 14). In patients with positive lymph nodes the SLN was predictive in all cases (six of six). In one case the only node with disease was the SLN, and in this case the disease was identified by only Imm; thus this patient was upstaged. SLN mapping is feasible and safe and can readily be performed in patients with colonic cancer. In conjunction with SLN mapping, Imm techniques may upstage a subset of patients likely to be at increased risk for metastatic disease. Consequently SLN mapping of colon cancer should be evaluated in large prospective trials.

Original languageEnglish
Pages (from-to)943-946
Number of pages4
JournalAmerican Surgeon
Volume66
Issue number10
StatePublished - 2000
Externally publishedYes

Fingerprint

Colon
Carcinoma
Colonic Neoplasms
Sentinel Lymph Node
Lymph Nodes
Carcinoembryonic Antigen
Hematoxylin
Standard of Care
Eosine Yellowish-(YS)
Operative Time
Keratins
Lymph Node Excision
Needles
Dissection
Melanoma
Adenocarcinoma
Coloring Agents
Breast Neoplasms
Biopsy

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Waters, G. S., Geisinger, K. R., Garske, D. D., Loggie, B. W., Levine, E. A., Foley, E. F., & Sharp, K. W. (2000). Sentinel lymph node mapping for carcinoma of the colon: A pilot study. American Surgeon, 66(10), 943-946.

Sentinel lymph node mapping for carcinoma of the colon : A pilot study. / Waters, G. S.; Geisinger, K. R.; Garske, D. D.; Loggie, Brian W.; Levine, E. A.; Foley, E. F.; Sharp, K. W.

In: American Surgeon, Vol. 66, No. 10, 2000, p. 943-946.

Research output: Contribution to journalArticle

Waters, GS, Geisinger, KR, Garske, DD, Loggie, BW, Levine, EA, Foley, EF & Sharp, KW 2000, 'Sentinel lymph node mapping for carcinoma of the colon: A pilot study', American Surgeon, vol. 66, no. 10, pp. 943-946.
Waters GS, Geisinger KR, Garske DD, Loggie BW, Levine EA, Foley EF et al. Sentinel lymph node mapping for carcinoma of the colon: A pilot study. American Surgeon. 2000;66(10):943-946.
Waters, G. S. ; Geisinger, K. R. ; Garske, D. D. ; Loggie, Brian W. ; Levine, E. A. ; Foley, E. F. ; Sharp, K. W. / Sentinel lymph node mapping for carcinoma of the colon : A pilot study. In: American Surgeon. 2000 ; Vol. 66, No. 10. pp. 943-946.
@article{f58d251c36fa4760ae196f078f893c1f,
title = "Sentinel lymph node mapping for carcinoma of the colon: A pilot study",
abstract = "Sentinel lymph node (SLN) mapping has evolved into the standard of care for melanoma and may replace routine node dissection in the treatment of breast cancer. There are few data evaluating sentinel node mapping in patients with cancer of the colon. This trial represents our initial experience with SLN mapping for carcinoma of the colon. SLN mapping was performed in 22 patients most of whom had biopsy-proven adenocarcinoma of the colon. One milliliter of isosulfan blue was injected with a 25-gauge needle into the subserosa at four sites around the edge of the palpable tumor. The SLN was identified visually and excised. A standard lymphadenectomy was then performed. The SLN was analyzed with standard hematoxylin and eosin evaluation. Immunohistochemical techniques for carcinoembryonic antigen and cytokeratin (Imm) were performed if the H and E was negative. The mapping added approximately 5 minutes to the total operative time and no adverse reactions to the dye occurred. A SLN was identified in 20 of 22 cases. In cases with negative lymph nodes the SLN was predictive of all the regional nodes by both H and E and Imm (14 of 14). In patients with positive lymph nodes the SLN was predictive in all cases (six of six). In one case the only node with disease was the SLN, and in this case the disease was identified by only Imm; thus this patient was upstaged. SLN mapping is feasible and safe and can readily be performed in patients with colonic cancer. In conjunction with SLN mapping, Imm techniques may upstage a subset of patients likely to be at increased risk for metastatic disease. Consequently SLN mapping of colon cancer should be evaluated in large prospective trials.",
author = "Waters, {G. S.} and Geisinger, {K. R.} and Garske, {D. D.} and Loggie, {Brian W.} and Levine, {E. A.} and Foley, {E. F.} and Sharp, {K. W.}",
year = "2000",
language = "English",
volume = "66",
pages = "943--946",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "10",

}

TY - JOUR

T1 - Sentinel lymph node mapping for carcinoma of the colon

T2 - A pilot study

AU - Waters, G. S.

AU - Geisinger, K. R.

AU - Garske, D. D.

AU - Loggie, Brian W.

AU - Levine, E. A.

AU - Foley, E. F.

AU - Sharp, K. W.

PY - 2000

Y1 - 2000

N2 - Sentinel lymph node (SLN) mapping has evolved into the standard of care for melanoma and may replace routine node dissection in the treatment of breast cancer. There are few data evaluating sentinel node mapping in patients with cancer of the colon. This trial represents our initial experience with SLN mapping for carcinoma of the colon. SLN mapping was performed in 22 patients most of whom had biopsy-proven adenocarcinoma of the colon. One milliliter of isosulfan blue was injected with a 25-gauge needle into the subserosa at four sites around the edge of the palpable tumor. The SLN was identified visually and excised. A standard lymphadenectomy was then performed. The SLN was analyzed with standard hematoxylin and eosin evaluation. Immunohistochemical techniques for carcinoembryonic antigen and cytokeratin (Imm) were performed if the H and E was negative. The mapping added approximately 5 minutes to the total operative time and no adverse reactions to the dye occurred. A SLN was identified in 20 of 22 cases. In cases with negative lymph nodes the SLN was predictive of all the regional nodes by both H and E and Imm (14 of 14). In patients with positive lymph nodes the SLN was predictive in all cases (six of six). In one case the only node with disease was the SLN, and in this case the disease was identified by only Imm; thus this patient was upstaged. SLN mapping is feasible and safe and can readily be performed in patients with colonic cancer. In conjunction with SLN mapping, Imm techniques may upstage a subset of patients likely to be at increased risk for metastatic disease. Consequently SLN mapping of colon cancer should be evaluated in large prospective trials.

AB - Sentinel lymph node (SLN) mapping has evolved into the standard of care for melanoma and may replace routine node dissection in the treatment of breast cancer. There are few data evaluating sentinel node mapping in patients with cancer of the colon. This trial represents our initial experience with SLN mapping for carcinoma of the colon. SLN mapping was performed in 22 patients most of whom had biopsy-proven adenocarcinoma of the colon. One milliliter of isosulfan blue was injected with a 25-gauge needle into the subserosa at four sites around the edge of the palpable tumor. The SLN was identified visually and excised. A standard lymphadenectomy was then performed. The SLN was analyzed with standard hematoxylin and eosin evaluation. Immunohistochemical techniques for carcinoembryonic antigen and cytokeratin (Imm) were performed if the H and E was negative. The mapping added approximately 5 minutes to the total operative time and no adverse reactions to the dye occurred. A SLN was identified in 20 of 22 cases. In cases with negative lymph nodes the SLN was predictive of all the regional nodes by both H and E and Imm (14 of 14). In patients with positive lymph nodes the SLN was predictive in all cases (six of six). In one case the only node with disease was the SLN, and in this case the disease was identified by only Imm; thus this patient was upstaged. SLN mapping is feasible and safe and can readily be performed in patients with colonic cancer. In conjunction with SLN mapping, Imm techniques may upstage a subset of patients likely to be at increased risk for metastatic disease. Consequently SLN mapping of colon cancer should be evaluated in large prospective trials.

UR - http://www.scopus.com/inward/record.url?scp=0033774364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033774364&partnerID=8YFLogxK

M3 - Article

C2 - 11261621

AN - SCOPUS:0033774364

VL - 66

SP - 943

EP - 946

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 10

ER -